New drug combo targets tough cancers in early trial

NCT ID NCT05431270

Recruiting now Disease control Sponsor: Phanes Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see if it helps shrink tumors. About 40 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Tranquility Research
TERMINATED

Webster, Texas, 77598, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.